{"nctId":"NCT01791153","briefTitle":"An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA)","startDateStruct":{"date":"2013-07-22","type":"ACTUAL"},"conditions":["Giant Cell Arteritis"],"count":251,"armGroups":[{"label":"Part 1: Tocilizumab qw + 26 weeks prednisone taper","type":"EXPERIMENTAL","interventionNames":["Drug: Tocilizumab","Drug: Prednisone","Drug: Prednisone Placebo"]},{"label":"Part 1: Tocilizumab q2w + 26 weeks prednisone taper","type":"EXPERIMENTAL","interventionNames":["Drug: Tocilizumab","Drug: Prednisone","Drug: Tocilizumab Placebo","Drug: Prednisone Placebo"]},{"label":"Part 1: Placebo + 26 weeks prednisone taper","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Prednisone","Drug: Tocilizumab Placebo","Drug: Prednisone Placebo"]},{"label":"Part 1: Placebo + 52 weeks prednisone taper","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Prednisone","Drug: Tocilizumab Placebo","Drug: Prednisone Placebo"]},{"label":"Part 2: Open-Label Tocilizumab qw","type":"EXPERIMENTAL","interventionNames":["Drug: Tocilizumab","Drug: Corticosteroids","Drug: Methotrexate"]}],"interventions":[{"name":"Tocilizumab","otherNames":["RoActemra, Actemra, RO4877533"]},{"name":"Prednisone","otherNames":[]},{"name":"Tocilizumab Placebo","otherNames":[]},{"name":"Prednisone Placebo","otherNames":[]},{"name":"Corticosteroids","otherNames":[]},{"name":"Methotrexate","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of GCA classified according to age \\>/=50 years; history of ESR \\>/=50 mm/hr or history of CRP \\>/=2.45 mg/dL; and at least one of the following: unequivocal cranial symptoms of GCA or symptoms of polymyalgia rheumatica \\[PMR\\]; and at least one of the following: temporal artery biopsy revealing features of GCA or evidence of large-vessel vasculitis by angiography or cross-sectional imaging\n* New onset (diagnosis within 6 weeks of baseline) or refractory (diagnosis greater than \\[\\>\\] 6 weeks before baseline and previous treatment with \\>/= 40 milligrams per day prednisone \\[or equivalent\\] for at least 2 consecutive weeks at any time) GCA\n* Active disease (presence of clinical signs and symptoms \\[cranial or PMR\\] and ESR \\>/=30 mm/hour or CRP \\>/=1 mg/dL) within 6 weeks of baseline visit\n\nExclusion Criteria:\n\n* Major surgery within 8 weeks prior to screening or planned within 12 months after randomization\n* Transplanted organs (except corneas with transplant performed \\>3 months prior to screening)\n* Major ischemic event, unrelated to GCA, within 12 weeks of screening\n* Prior treatment with any of the following: investigational agent within 12 weeks (or 5 half-lives of the investigational drug, whichever is longer) of screening; cell-depleting therapies including investigational agent; intravenous (IV) gamma globulin or plasmapheresis within 6 months of baseline; alkylating agents or with total lymphoid irradiation; tocilizumab; hydroxychloroquine, cyclosporine A, azathioprine, or mycophenolate mofetil within 4 weeks of baseline; etanercept within 2 weeks of baseline; infliximab, certolizumab, golimumab, abatacept, or adalimumab within 8 weeks of baseline; anakinra within 1 week of baseline; tofacitinib; cyclophosphamide within 6 months of baseline; \\>100 milligrams of daily IV methylprednisolone within 6 weeks of baseline\n* Participants requiring systemic glucocorticoids for conditions other than GCA, which, in the opinion of the investigator, would interfere with adherence to the fixed glucocorticoid taper regimen and/or to assessment of efficacy in response to the test article\n* History of severe allergic reactions to monoclonal antibodies or to prednisone\n* Evidence of serious uncontrolled concomitant disease (for example, cardiovascular, respiratory, renal, endocrine, psychiatric, corneal ulcers/injuries, or gastrointestinal \\[GI\\] disease)\n* Current liver disease, as determined by the investigator\n* History of diverticulitis, inflammatory bowel disease, or other symptomatic GI tract condition that might predispose to bowel perforation\n* Known active or history of recurrent bacterial, viral fungal, mycobacterial, or other infection\n* Primary or secondary immunodeficiency\n* Evidence of malignancies diagnosed within previous 5 years (except basal and squamous cell carcinoma of the skin or carcinoma in situ of the cervix uteri that have been excised and cured)\n* Inadequate hematologic, renal or liver function\n* Positive for hepatitis B or hepatitis C infection","healthyVolunteers":false,"sex":"ALL","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants in Sustained Remission at Week 52 (Tocilizumab + 26 Weeks Prednisone Taper Versus Placebo + 26 Weeks Prednisone Taper)","description":"Remission was defined as the absence of flare and normalization of the C-reactive protein (CRP) (less than \\[\\<\\] 1 milligram per deciliter \\[mg/dL\\]). Sustained remission was defined as the absence of flare following induction of remission within 12 weeks of randomization and maintained up to Week 52. Flare was determined by the investigator and was defined as the recurrence of signs or symptoms of GCA and/or erythrocyte sedimentation rate (ESR) greater than or equal to (\\>/=) 30 millimeters per hour (mm/hr) attributable to GCA. A single CRP elevation (\\>/=1 mg/dL) was not considered as a sign of flare, unless the CRP remained elevated (\\>/=1 mg/dL) at the next study visit.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.0","spread":null},{"groupId":"OG001","value":"53.1","spread":null},{"groupId":"OG002","value":"14.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants in Sustained Remission at Week 52 (Tocilizumab + 26 Weeks Prednisone Taper Versus Placebo + 52 Weeks Prednisone Taper)","description":"Remission was defined as the absence of flare and normalization of the CRP (\\<1 mg/dL). Sustained remission was defined as the absence of flare following induction of remission within 12 weeks of randomization and maintained up to Week 52. Flare was determined by the investigator and was defined as the recurrence of signs or symptoms of GCA and/or ESR \\>/=30 mm/hr attributable to GCA. A single CRP elevation (\\>/=1 mg/dL) was not considered as a sign of flare, unless the CRP remained elevated (\\>/=1 mg/dL) at the next study visit.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.0","spread":null},{"groupId":"OG001","value":"53.1","spread":null},{"groupId":"OG002","value":"17.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First GCA Disease Flare","description":"Flare was determined by the investigator and was defined as the recurrence of signs or symptoms of GCA and/or ESR \\>/=30 mm/hr attributable to GCA. Participants who withdrew from the study prior to Week 52 were censored from the time of withdrawal.","paramType":"MEDIAN","dispersionType":"99% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"165.0","spread":null},{"groupId":"OG003","value":"295.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Cumulative Prednisone Dose","description":"The median total cumulative prednisone dose over the 52 weeks for each treatment group and the corresponding 95% confidence intervals are presented.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1862.00","spread":null},{"groupId":"OG001","value":"1862.00","spread":null},{"groupId":"OG002","value":"3296.00","spread":null},{"groupId":"OG003","value":"3817.50","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Short Form (SF)-36 Questionnaire Score at Week 52","description":"The SF-36 is a standardized questionnaire used to assess physical functioning and is made up of eight domains: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional and Mental Health. Transforming and standardizing these domains leads to the calculation of the Physical Component Score (PCS) and Mental Component Score (MCS). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). A positive change from baseline indicates improvement. No imputation was used for missing data. Data was set to missing for participants who received escape therapy.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.10","spread":"9.43"},{"groupId":"OG001","value":"40.62","spread":"8.00"},{"groupId":"OG002","value":"42.65","spread":"10.87"},{"groupId":"OG003","value":"41.12","spread":"9.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.37","spread":"7.38"},{"groupId":"OG001","value":"2.71","spread":"8.86"},{"groupId":"OG002","value":"2.08","spread":"12.11"},{"groupId":"OG003","value":"-2.80","spread":"6.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.77","spread":"12.43"},{"groupId":"OG001","value":"47.67","spread":"12.59"},{"groupId":"OG002","value":"42.73","spread":"12.13"},{"groupId":"OG003","value":"40.45","spread":"13.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.21","spread":"10.35"},{"groupId":"OG001","value":"1.98","spread":"7.17"},{"groupId":"OG002","value":"4.99","spread":"7.54"},{"groupId":"OG003","value":"2.60","spread":"10.56"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Patient Global Assessment (PGA) of Disease Activity Assessed Using Visual Analogue Scale (VAS) at Week 52","description":"Participants assessed their current disease activity on a 0-100 millimeter (mm) VAS, where 0 mm = no disease activity and 100 mm = maximum disease activity. A negative change from baseline indicates improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.61","spread":"25.66"},{"groupId":"OG001","value":"46.65","spread":"25.60"},{"groupId":"OG002","value":"35.73","spread":"28.15"},{"groupId":"OG003","value":"47.78","spread":"27.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.68","spread":"33.64"},{"groupId":"OG001","value":"-22.69","spread":"22.41"},{"groupId":"OG002","value":"-8.45","spread":"24.81"},{"groupId":"OG003","value":"-10.00","spread":"35.12"}]}]}]},{"type":"SECONDARY","title":"Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) at Steady State of Tocilizumab","description":"AUCtau is the model-predicted area under the tocilizumab serum concentration versus time curve from time zero to the end of dosing interval. AUCtau is measured in microgram\\*day per milliliter (mcg\\*day/mL).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"499.2","spread":"210.4"},{"groupId":"OG001","value":"227.2","spread":"165.4"}]}]}]},{"type":"SECONDARY","title":"Maximum Serum Concentration at Steady State (Cmax,ss) of Tocilizumab","description":"Cmax,ss is maximum model-predicted serum steady state concentration of tocilizumab measured in micrograms per milliliter (mcg/mL).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":"30.4"},{"groupId":"OG001","value":"19.3","spread":"12.8"}]}]}]},{"type":"SECONDARY","title":"Minimum Serum Concentration at Steady State (Cmin,ss) of Tocilizumab","description":"Cmin,ss is minimum model-predicted serum steady state concentration of tocilizumab measured in mcg/mL.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.1","spread":"29.5"},{"groupId":"OG001","value":"11.1","spread":"10.3"}]}]}]},{"type":"SECONDARY","title":"Minimum Observed Serum Concentration (Ctrough) of Tocilizumab","description":"Ctrough is minimum observed serum concentration of tocilizumab measured in mcg/mL.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":"0.72"},{"groupId":"OG001","value":"0.00","spread":"0.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.93","spread":"34.40"},{"groupId":"OG001","value":"12.22","spread":"10.02"}]}]}]},{"type":"SECONDARY","title":"Serum Interleukin-6 (IL-6) Level","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.79","spread":"10.01"},{"groupId":"OG001","value":"16.29","spread":"31.23"},{"groupId":"OG002","value":"12.73","spread":"18.04"},{"groupId":"OG003","value":"8.31","spread":"9.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.99","spread":"84.92"},{"groupId":"OG001","value":"52.70","spread":"33.10"},{"groupId":"OG002","value":"35.96","spread":"149.65"},{"groupId":"OG003","value":"10.85","spread":"15.17"}]}]}]},{"type":"SECONDARY","title":"Serum Soluble IL-6 Receptor (sIL-6R) Level","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.34","spread":"61.98"},{"groupId":"OG001","value":"50.82","spread":"63.51"},{"groupId":"OG002","value":"42.07","spread":"11.32"},{"groupId":"OG003","value":"40.37","spread":"10.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"600.53","spread":"217.52"},{"groupId":"OG001","value":"464.30","spread":"153.64"},{"groupId":"OG002","value":"76.44","spread":"149.20"},{"groupId":"OG003","value":"64.80","spread":"105.13"}]}]}]},{"type":"SECONDARY","title":"Erythrocyte Sedimentation Rate (ESR)","description":"ESR is a laboratory test that provides a non-specific measure of inflammation. The test assesses the rate at which red blood cells fall in a test tube. Normal range is 0-30 mm/hr. A higher rate is consistent with inflammation.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.00","spread":"61.98"},{"groupId":"OG001","value":"15.00","spread":"63.51"},{"groupId":"OG002","value":"23.00","spread":"11.32"},{"groupId":"OG003","value":"20.00","spread":"10.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.00","spread":null},{"groupId":"OG001","value":"5.00","spread":null},{"groupId":"OG002","value":"20.00","spread":null},{"groupId":"OG003","value":"24.00","spread":null}]}]}]},{"type":"SECONDARY","title":"C-Reactive Protein (CRP) Level","description":"The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.67","spread":"61.98"},{"groupId":"OG001","value":"4.52","spread":"63.51"},{"groupId":"OG002","value":"3.64","spread":"11.32"},{"groupId":"OG003","value":"3.56","spread":"10.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.30","spread":null},{"groupId":"OG001","value":"0.33","spread":null},{"groupId":"OG002","value":"4.90","spread":null},{"groupId":"OG003","value":"8.12","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Anti-Tocilizumab Antibodies","description":"All samples were tested by screening assay, and those samples that were positive were further analyzed by a confirmation assay to confirm specificity. Percentage of participants who has a positive confirmation assay result any time after the initial drug administration with a negative confirmation assay result at baseline was reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":null},{"groupId":"OG001","value":"6.5","spread":null},{"groupId":"OG002","value":"2.0","spread":null},{"groupId":"OG003","value":"2.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":15,"n":100},"commonTop":["Nasopharyngitis","Headache","Arthralgia","Back pain","Oedema peripheral"]}}}